NSCLC MET dysregulations in the form of MET amplification (METamp) have also been shown to act as secondary drivers that can mediate resistance to targeted therapy for other oncogenes such as epidermal growth factor receptor (EGFR) mutations [7,8,16]. This evidence concerns the gene MET and non-small cell lung carcinoma.